Clinical trial NCT04131712: Mechanisms Underlying Local and Systemic Effects of Massage
Official title: Mechanisms Underlying Local and Systemic Effects of Massage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Muscle Atrophy
Keywords: Massage
Muscle
Extracellular Vesicles
Atrophy
Lead sponsor: University of Kentucky
Sponsor class: OTHER
Collaborators: name: University of Oklahoma
name: National Center for Complementary and Integrative Health (NCCIH)
First posted: 2019-10-18
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether massage can attenuate the loss of muscle mass in humans after a short period of disuse.

Detailed description: The loss of skeletal muscle mass is a common symptom associated with diseases such as cancer, AIDS, diabetes, and congestive heart failure, and with aging. Muscle atrophy is associated with poor disease prognosis and decreased quality of life and therefore, maintaining muscle size and reducing the loss of muscle during disuse atrophy is of vital significance. Mechanical stimulation of muscle, such as during resistance exercise, stimulates protein synthesis that increases muscle protein content, and muscle size. The investigators have shown that mechanical stimulation applied to skeletal muscle in the form of massage is an effective mechanotherapy in rats, since it leads to a shift in protein turnover favoring anabolism, attenuation of muscle loss and enhanced regrowth after disuse-induced atrophy. Whether the same positive effect of massage occurs in humans is currently unknown, but would be extremely beneficial for skeletal muscle and overall health in case where resistance exercise is contraindicated or not feasible. In addition to the direct anabolic effects on the massaged rat muscle, the investigators have shown an equally beneficial response on the homologous muscle in the contralateral non-massaged limb. This novel finding indicated the existence of indirect mechanisms that could have profound systemic effects beyond the massaged muscle. Extracellular vesicles (EVs) are lipid membrane-bound vesicles released from cells with the ability to modulate function of cells from which they are released, as well as in cells with which they fuse. As such EVs are likely mediators of the well-documented but poorly-understood effects of massage in humans on the brain and other organs, such as relief of pain, anxiety or depression or changes in immunity. Therefore, the goal of this proposal is to determine anabolic effects of massage in human muscle, and to identify whether EVs released with massage are candidates for beneficial effects of this mechanotherapy on muscle as well as other organs. In Aim 1 the investigators will address the following hypothesis: Massage acts as a mechanotherapy by attenuating muscle atrophy through a shift in protein biogenesis towards anabolism in humans. Using a novel massage device we will apply mechanical load to muscle undergoing atrophy through unilateral lower limb suspension and muscle size as well as protein synthesis and degradation will be determined. In Aim 2 the investigators will test the hypothesis that massage attenuates the loss of EVs during atrophy by enhancing EV biogenesis in muscle. The investigators will measure EVs and their miRNA cargo in the serum, and markers of EV biogenesis in muscle of human subjects from Aim 1. Results from this study will indicate not only whether mechanotherapy, such as massage, can attenuate atrophy and enhance anabolic processes during disuse, but also determine whether EVs are a candidate mechanism for the overall health benefits of massage.

Eligibility criteria: Inclusion Criteria:

* Men and women 18-30 years of age.
* All races and ethnic backgrounds.
* Non-smoker and generally healthy.

Exclusion Criteria:

* Have a current lower extremity musculoskeletal injury or compromised musculoskeletal function that would not allow the safe use of crutches or a brace.
* Previous lower extremity surgeries or injury.
* Activities of daily living require long periods of standing or driving a manual transmission car.
* Body mass index (BMI) under 27.
* Evidence or signs and symptoms of metabolic syndrome or disorder (diagnosis of diabetes or insulin resistance, elevated BP, high fasting blood sugar, abnormal cholesterol or triglyceride levels).
* Thyroid disorder.
* Acute or chronic infections.
* Use of systemic steroids, anabolic steroids, or growth hormone.
* Chronic aspirin or NSAID use (unless it can be safely stopped prior to the biopsies), and any other use of an anticoagulant (e.g., Coumadin) or history of bleeding including history of hypo- or hyper-coagulation disorders.
* Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle biopsy procedure).
* Any other condition or events considered exclusionary by the PI and/or physician, such as non-compliance.
* Pregnancy.

Primary outcomes:
measure: Percent Change in Myofiber Cross Sectional Area (CSA).
timeFrame: 9 days
measure: Myofibrillar Protein Synthesis Rate (MyoKsyn).
timeFrame: 9 days
Secondary outcomes:
measure: Percent Change in Serum Extracellular Vesicle Number (EV #).
timeFrame: 9 days
measure: Percent Change in the Expression of Muscle Rab27b mRNA.
timeFrame: 9 days
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: Esther Dupont-Versteegden, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: